Skip navigation.
Cappolino, Dodd, Krebs, LLP

www.AsbestosLaw.com

No Fee Until We Win
1-(888)-MESO-FIRM

1-(888)-637-6347

Serving Clients Nationwide

Rss Feed Twitter Link Facebook Link Linked In Link



Archive for the ‘Lung Cancer’ Category

National Cancer Data Shows Lung Cancer Rates in Women Have Declined

Friday, April 1st, 2011

According to CNN, lung rates in women have fallen for the first time in a decade. A new report released by the National Cancer Institute showed that data collected through The American Cancer Society, The North American Association of Central Cancer Registries and the Center for Diseases Control and Prevention showed that lung cancer rates in women dropped significantly in time period of 2003-2007. This follows a long-term increase in lung cancer death rates in women for the past three decades.

The report found a significant decrease in cancer death rates for men and women since the early 1990s. However, death rates from liver cancer and melanoma in men, and liver and pancreatic cancer in women continue to increase.

The rate of new cancers, in both men and women, fell on average 1 percent a year, according to data collected. The percentage of prostate cancer cases has increased. Common cancers found in men such as lung, colorectal, oral, stomach and malignant tumors have decreased, while women saw decreases in breast, lung, colorectal, uterus, cervix, bladder and oral cavity cancers.

Unfortunately, pediatric cancer diagnosis have seen an increase in children from birth to 19 years of age.

It is gratifying to see some decline in overall cancer incidence and death rates in the United States. It shows that various methods for preventing, early detection and treatment has significantly improved. The American Association for Cancer Research calls the data remarkable, as it highlights the progress against cancer, and shows that increased knowledge, science, and advances in technology have done a lot to reduce incidence and mortality rates of cancer.

Lung Cancer Drug Fails Advanced Late Stage Study

Thursday, March 17th, 2011

According to Fox News, a lung cancer drug motesanib has failed in a late-stage study. Amgen Inc. and Takeda Pharmaceutical Co. announced the drug being developed by the companies has failed in a late-stage testing to improve overall survival rates for lung cancer patients.

The two companied developed motesanib for patients with non-squamous non-small cell lung cancer. Patients included in the study were receiving either a combination of the drug with chemotherapy or a placebo with chemotherapy. Squamous refers to the type of cancer cells from which the cancer originated.

The patients, as in earlier trials of motesanib, were also more likely to experience serious adverse events more frequently than those with a placebo. Some of the adverse events reported included hypertension and bleeding disorders.

The companies reported disappointment over motesanib failure, but plan to analyze the data closely in order to prepare for further research in the lung cancer area.

In 2008, another study involving the same drug was halted after early data showed higher mortality rates among patients receiving the drug. In 2009, the companies resumed the study with only non-squamous patients, as those patients are more likely to cough up blood during testing. Non-squamous non-small cell lung cancer affects about two-thirds of all non-small lung cancers. The company expected sales of motesanib to reach about $912 million by 2017.

Diabetes Medications Used to Treat Lung Cancer

Monday, January 17th, 2011

Recent findings have shown that previous studies concerning the use of diabetes medications to treat lung cancer were essentially on the money. Certain diabetes medications such as metformin have shown to slow the progression of lung cancer and to provide a longer life.

The new study evaluated the reaction of the cancerous cells in people who had diabetes and/ or lung cancer and were exposed to metformin or other diabetes drugs known as TZDs before the lung cancer diagnosis. Of the diabetics monitored, people who were on the diabetic medications were less like to develop lung cancer, and those who had already been diagnosed with lung cancer were less likely to experience spreading and have a better chance of survival if they were on one of these medications before the diagnosis.

The results show that the people who take the diabetes medications seem to develop lung cancer less often. The numbers don’t lie, 96% of the people involved did not develop lung cancer while taking the drugs. Why the diabetes drugs seem to make lung cancer less likely and when it does occur make it less likely to spread isn’t known. The drugs work through several pathways that are also known to slow the development and growth of cancer cells.

The goal of this research is to eventually be able to identify patients that have a high risk of developing lung cancer and preventing it by starting them on medications before the fact. There are side effects and the results and treatments have not been fully developed, but the scientists and doctors are working toward it every day.

Metformin May Be a Lung Cancer Preventative

Thursday, January 6th, 2011

Can your average everyday diabetes medication, help prevent lung cancer? Studies have shown that metformin has been linked to lower cancer rates. However it has also been found that metformin can impede the growth of lung tumors caused by tobacco carcinogens.

This is because metformin activates an enzyme known as AMP- activated protein kinase. A study being b=presented this week in British Columbia is announcing that metformin and other diabetes drugs such as thiazolidedione or more simply TZDs can slow the progression of lung cancer and prevent metastatic development.

These drugs are now recognized as being a viable resource treatment to contain the spread of cancer and to also make the development of lung cancer less likely. There are several different pathways these drugs work through that could slow the growth of cancer cells and also affect the pathways that hare known for leading to cancer cell growth.

There are always studies being performed to fight cancer in all its forms, each and every discovery no matter how small can have a huge impact on the way this deadly disease is treated. Cancer has affected nearly all people in some way or another and the many different forms of cancer has baffled scientists and doctors who are searching for prevention and treatment options. This discovery of the use of metformin to treat lung cancer is a real breakthrough that may be able to be used to treat other forms of cancer as well.